- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01121822
Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intramuscular Route)
Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intramuscular Route)
The aim of this study is to evaluate the new formulation of the influenza vaccine for the 2010-2011 Northern Hemisphere (NH) season in terms of immunogenicity and safety in the corresponding population and to check its compliance with the Committee for Proprietary Medicinal Products (CPMP) Note for Guidance (NfG) CPMP/BWP/214/96
Objectives:
- To evaluate the compliance, in terms of immunogenicity, of the influenza vaccine (split virion, inactivated) NH 2010-2011 formulation with the requirements of the Committee for Proprietary Medicinal Products (CPMP) Note for Guidance (NfG) CPMP/BWP/214/96 in both age groups
- To describe the safety of the influenza vaccine (split virion, inactivated) NH 2010-2011 formulation in both age groups
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Gieres, France, 38610
-
MONTPELLIER Cedex 5, France, 34094
-
Rouffach, France, 68250
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria :
- Aged 18 years or over on the day of inclusion
- Informed consent form has been signed and dated
- Able to attend all scheduled visits and to comply with all trial procedures
- For a woman of childbearing potential, use of an effective method of contraception or abstinence from at least 4 weeks prior to vaccination until at least 4 weeks after vaccination
- Entitled to national social security.
Exclusion Criteria :
- Febrile illness (temperature ≥ 38.0°C) or moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination
- Known systemic hypersensitivity to eggs, chicken proteins, neomycin, formaldehyde and octoxynol-9, or to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances
- Known pregnancy, or a positive urine pregnancy test
- Currently breastfeeding a child
- History of pandemic H1N1 influenza vaccination
- History of clinically or laboratory confirmed pandemic H1N1 influenza infection
- History of influenza vaccination within the previous 6 months (other than pandemic H1N1 influenza vaccine)
- Receipt of an adjuvanted influenza vaccine in a clinical trial within the previous 12 months
Known or suspected congenital or acquired immunodeficiency, resulting for example from:
- End-stage renal disease requiring dialysis
- Active neoplastic disease or active hematologic malignancy
- Receipt of immunosuppressive therapy or other immune-modifying drugs such as, but not limited to: anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- History of seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C
- Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response
- Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion
- History of thrombocytopenia, contraindicating intramuscular (IM) vaccination
- Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination
- Receipt of any vaccine in the 4 weeks preceding the trial vaccination
- Planned receipt of any vaccine in the 3 weeks following the trial vaccination
- Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the trial vaccination
- Planned participation in another clinical trial during the present trial period
- Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
- Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures
- Identified as employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the employees or the Investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
Participants at age 18 to 59 years
|
0.5 mL, Intramuscular
|
Experimental: Group 2
Participants at age 60 years or older
|
0.5 mL, Intramuscular
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To provide information concerning the immunogenicity of the Influenza virus vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation.
Time Frame: 21 days post-vaccination
|
21 days post-vaccination
|
Safety: To provide information concerning the safety of the Influenza virus vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation.
Time Frame: 21 days post-vaccination
|
21 days post-vaccination
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GRT90
- 2009-017690-38 (EudraCT Number)
- UTN: U1111-1112-8285 (Other Identifier: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
NPO PetrovaxCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Acute Respiratory Infection | Influenza Type B | Flu | Influenza A H3N2 | Influenza A H1N1 | Flu, Human | Influenza EpidemicRussian Federation
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)CompletedInfluenza AUnited States
Clinical Trials on Influenza virus vaccine (split virion, inactivated)
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza | Orthomyxoviridae InfectionsBelgium, Germany, Switzerland
-
Butantan InstituteFundação ButantanRecruiting
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza | Swine-origin A/H1N1 InfluenzaFinland
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza | Orthomyxoviridae InfectionsAustralia
-
Sanofi Pasteur, a Sanofi CompanyCompleted
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza | Orthomyxoviridae InfectionsBelgium, United Kingdom
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza | Myxovirus Infection | Orthomyxovirus InfectionsFrance
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza | Orthomyxoviridae InfectionsFrance
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza | Orthomyxoviridae Infection | Myxovirus InfectionAustralia, New Zealand
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza | Orthomyxoviridae InfectionsSwitzerland, United Kingdom